This company listing is no longer active
QSOA Stock Overview
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Surface Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.99 |
| 52 Week High | US$1.41 |
| 52 Week Low | US$0.52 |
| Beta | 1.75 |
| 1 Month Change | 16.19% |
| 3 Month Change | 36.16% |
| 1 Year Change | -27.10% |
| 3 Year Change | -82.41% |
| 5 Year Change | -88.77% |
| Change since IPO | -90.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| QSOA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -0.7% | -13.4% | -1.3% |
| 1Y | -27.1% | -17.3% | 14.9% |
Return vs Industry: QSOA underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: QSOA underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| QSOA volatility | |
|---|---|
| QSOA Average Weekly Movement | 12.0% |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: QSOA's share price has been volatile over the past 3 months.
Volatility Over Time: QSOA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 35 | Rob Ross | www.surfaceoncology.com |
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No.
Surface Oncology, Inc. Fundamentals Summary
| QSOA fundamental statistics | |
|---|---|
| Market cap | €60.83m |
| Earnings (TTM) | -€86.46m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs QSOA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QSOA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$67.00m |
| Gross Profit | -US$67.00m |
| Other Expenses | US$25.50m |
| Earnings | -US$92.50m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.52 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did QSOA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/09/08 06:15 |
| End of Day Share Price | 2023/09/07 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Surface Oncology, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Ulz | Baird |
| Justin Zelin | BTIG |
| Joshua Schimmer | Evercore ISI |